Last reviewed · How we verify
azacitidine for injectable suspension — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
azacitidine for injectable suspension (azacitidine for injectable suspension) — US Oncology Research.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| azacitidine for injectable suspension TARGET | azacitidine for injectable suspension | US Oncology Research | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- azacitidine for injectable suspension CI watch — RSS
- azacitidine for injectable suspension CI watch — Atom
- azacitidine for injectable suspension CI watch — JSON
- azacitidine for injectable suspension alone — RSS
Cite this brief
Drug Landscape (2026). azacitidine for injectable suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/azacitidine-for-injectable-suspension. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing